1,396
Views
13
CrossRef citations to date
0
Altmetric
Clinical

Whole body hyperthermia treatment increases interleukin 10 and toll-like receptor 4 expression in patients with ankylosing spondylitis: A pilot study

, , , , , , , & show all
Pages 393-401 | Received 16 Jun 2014, Accepted 18 Aug 2014, Published online: 26 Sep 2014

Figures & data

Figure 1. Polymorphonuclear leukocyte counts. Symbols and abbreviations: Δ patients; ○ healthy control subjects;

, total duration of hyperthermia treatment including active heating and heat retention period; bef, baseline measurements immediately before start of hyperthermia treatment around 7:00 a.m.; 0, end of active heating period (achievement of target body core temperature); 1, 1 h after end of active heating (end of heat retention period); 2, 2 h after end of active heating; 3, 3 h after end of active heating; 24, 24 h after end of active heating.

Figure 1. Polymorphonuclear leukocyte counts. Symbols and abbreviations: Δ patients; ○ healthy control subjects; Display full size, total duration of hyperthermia treatment including active heating and heat retention period; bef, baseline measurements immediately before start of hyperthermia treatment around 7:00 a.m.; 0, end of active heating period (achievement of target body core temperature); 1, 1 h after end of active heating (end of heat retention period); 2, 2 h after end of active heating; 3, 3 h after end of active heating; 24, 24 h after end of active heating.

Figure 2. Lymphocyte subsets. Symbols and abbreviations: Δ patients; ○ healthy control subjects;

, total duration of hyperthermia treatment including active heating and heat retention period; bef, baseline measurements immediately before start of hyperthermia treatment around 7:00 a.m.; 0, end of active heating period (achievement of target body core temperature); 1, 1 h after end of active heating (end of heat retention period); 2, 2 h after end of active heating; 3, 3 h after end of active heating; 24, 24 h after end of active heating.

Figure 2. Lymphocyte subsets. Symbols and abbreviations: Δ patients; ○ healthy control subjects; Display full size, total duration of hyperthermia treatment including active heating and heat retention period; bef, baseline measurements immediately before start of hyperthermia treatment around 7:00 a.m.; 0, end of active heating period (achievement of target body core temperature); 1, 1 h after end of active heating (end of heat retention period); 2, 2 h after end of active heating; 3, 3 h after end of active heating; 24, 24 h after end of active heating.

Table 1. Effects of hyperthermia on polymorphonuclear leucocytes and lymphocyte subsets (q-values).

Figure 3. TLR-4, IL-10 and HSPB1 gene expression. Symbols and abbreviations: Δ patients; ○ healthy control subjects;

, total duration of hyperthermia treatment including active heating and heat retention period; bef, baseline measurements immediately before start of hyperthermia treatment around 7:00 a.m.; 0, end of active heating period (achievement of target body core temperature); 1, 1 h after end of active heating (end of heat retention period); 2, 2 h after end of active heating; 3, 3 h after end of active heating; 24, 24 h after end of active heating.

Figure 3. TLR-4, IL-10 and HSPB1 gene expression. Symbols and abbreviations: Δ patients; ○ healthy control subjects; Display full size, total duration of hyperthermia treatment including active heating and heat retention period; bef, baseline measurements immediately before start of hyperthermia treatment around 7:00 a.m.; 0, end of active heating period (achievement of target body core temperature); 1, 1 h after end of active heating (end of heat retention period); 2, 2 h after end of active heating; 3, 3 h after end of active heating; 24, 24 h after end of active heating.

Table 2. Effects of hyperthermia treatment on TLR-4, IL-10 and HSPB1 gene expression (q-values).

Figure 4. Systemic cytokines. Symbols and abbreviations: Δ patients; ○ healthy control subjects;

, total duration of hyperthermia treatment including active heating and heat retention period; bef, baseline measurements immediately before start of hyperthermia treatment around 7:00 a.m.; 0, end of active heating period (achievement of target body core temperature); 1, 1 h after end of active heating (end of heat retention period); 2, 2 h after end of active heating; 3, 3 h after end of active heating; 24, 24 h after end of active heating.

Figure 4. Systemic cytokines. Symbols and abbreviations: Δ patients; ○ healthy control subjects; Display full size, total duration of hyperthermia treatment including active heating and heat retention period; bef, baseline measurements immediately before start of hyperthermia treatment around 7:00 a.m.; 0, end of active heating period (achievement of target body core temperature); 1, 1 h after end of active heating (end of heat retention period); 2, 2 h after end of active heating; 3, 3 h after end of active heating; 24, 24 h after end of active heating.

Table 3. Effects of hyperthermia treatment on plasma cytokine concentrations (q-values).

Figure 5. Acute phase reactants. Symbols and abbreviations: Δ patients; ○ healthy control subjects;

, total duration of hyperthermia treatment including active heating and heat retention period; bef, baseline measurements immediately before start of hyperthermia treatment around 7:00 a.m.; 0, end of active heating period (achievement of target body core temperature); 1, 1 h after end of active heating (end of heat retention period); 2, 2 h after end of active heating; 3, 3 h after end of active heating; 24, 24 h after end of active heating.

Figure 5. Acute phase reactants. Symbols and abbreviations: Δ patients; ○ healthy control subjects; Display full size, total duration of hyperthermia treatment including active heating and heat retention period; bef, baseline measurements immediately before start of hyperthermia treatment around 7:00 a.m.; 0, end of active heating period (achievement of target body core temperature); 1, 1 h after end of active heating (end of heat retention period); 2, 2 h after end of active heating; 3, 3 h after end of active heating; 24, 24 h after end of active heating.

Table 4. Effects of hyperthermia treatment on acute phase reactants (q-values).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.